Immune Checkpoint Inhibitors in Unresectable or Metastatic Thymic Epithelial Tumors––A Real-World Assessment of Efficacy and Toxicity
Clinical Lung Cancer · 2026-06 · 27 (5) · 29-37
DOI: 10.1016/j.cllc.2026.04.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026-06. Verfasst von Guilherme Sacchi de Camargo Correia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL; Georgia Cancer Center at Augusta University, Augusta, GA. Hauptthemen laut MEDLINE: Thymus Neoplasms, Immune Checkpoint Inhibitors, Neoplasms, Glandular and Epithelial. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Thymic epithelial tumors (TET) are rare, with limited prospective data on their management. While studied in the second-line setting and beyond, real-world data on immune checkpoint inhibitors (ICIs) outcomes are lacking. We assessed the real-world efficacy and safety of ICIs in TET, and investigated the correlation between immune-related adverse events (irAEs) and clinical outcomes. We retrospectively reviewed patients with unresectable or metastatic TET treated with ICIs at 5 Mayo Clinic sites. Baseline characteristics, outcomes, and toxicity data were collected. We calculated the overall response rate (ORR), median progression-free survival (mPFS), median overall survival (mOS), and assessed their correlation with irAEs. Thirty patients were included (28 with thymic carcinoma, 2 with thymoma). Pembrolizumab was used in 29 patients, and durvalumab in one. The ORR was 23.3%. The mPFS was 10.12 months and did not differ by irAEs incidence (hazard ratio (HR) 0.99, 95% confidence interval (CI), 0.39-2.54). 40.0% of patients had irAEs, which were predominantly grade 2 (61.5%), and most commonly thyroiditis (26.7%). The mOS was 81.3 months, numerically longer in those with irAEs versus those without (81.3 vs. 58.6 months; HR 0.51, 95% CI, 0.13-1.97). The ORR was similar to data published in the literature, although mPFS and mOS were numerically longer. The incidence of irAEs was higher but less severe than in prior data. irAEs did not significantly correlate with outcomes, despite a trend toward prolonged mOS. Further studies are needed to identify biomarkers, optimize both patient selection and toxicity management, and improve TET outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL; Georgia Cancer Center at Augusta University, Augusta, GA.
- Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL.
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.
- Department of Oncology, Mayo Clinic, Rochester, MN.
- Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL. Electronic address: manochakian.rami@mayo.edu.
Zitieren
APA
Sacchi de Camargo Correia, G., Tawfiq, R., Chen, R., Lou, Y., Zhao, Y., Li, S., Velcheti, V., Ernani, V., Parikh, K., & Manochakian, R. (2026). Immune Checkpoint Inhibitors in Unresectable or Metastatic Thymic Epithelial Tumors––A Real-World Assessment of Efficacy and Toxicity. Clinical Lung Cancer, 27(5), 29-37. https://doi.org/10.1016/j.cllc.2026.04.012
Vancouver
Sacchi de Camargo Correia G, Tawfiq R, Chen R, Lou Y, Zhao Y, Li S, et al. Immune Checkpoint Inhibitors in Unresectable or Metastatic Thymic Epithelial Tumors––A Real-World Assessment of Efficacy and Toxicity. Clinical Lung Cancer. 2026;27(5):29-37. doi:10.1016/j.cllc.2026.04.012
BibTeX
@article{SacchideCamargoCorreia2026,
author = {Sacchi de Camargo Correia, Guilherme and Tawfiq, Reema and Chen, Ruqin and Lou, Yanyan and Zhao, Yujie and Li, Shenduo and Velcheti, Vamsidhar and Ernani, Vinicius and Parikh, Kaushal and Manochakian, Rami},
title = {Immune Checkpoint Inhibitors in Unresectable or Metastatic Thymic Epithelial Tumors––A Real-World Assessment of Efficacy and Toxicity},
journal = {Clinical Lung Cancer},
year = {2026},
volume = {27},
number = {5},
pages = {29--37},
doi = {10.1016/j.cllc.2026.04.012}
}
EUVIMED